Abstracts Archive - Page 1560 of 2607 - ACR Meeting Abstracts

Abstract Number: 2591 • 2017 ACR/ARHP Annual Meeting
Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab
Victoria P Werth¹, Gabor Illei², Gabriel Abreu³, Liangwei Wang² and Warren Greth², ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²MedImmune, Gaithersburg, MD, ³AstraZeneca, Gothenburg, Sweden
Background/Purpose: Studies have demonstrated an association between smoking and more severe cutaneous lupus erythematosus, resulting in decreased health-related quality of life and treatment response.1 We…
Abstract Number: 2592 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Raj Tummala¹, Tomas Rouse², Anna Berglind² and Linda Santiago³, ¹AstraZeneca, Gaithersburg, MD, ²AstraZeneca, Gothenberg, Sweden, ³MedImmune, LLC, Mountain View, CA
Background/Purpose: Anifrolumab is a fully human anti–interferon-ɑ receptor 1 monoclonal antibody in Phase III development as an intravenous (IV) therapeutic for systemic lupus erythematosus (SLE).…
Abstract Number: 2593 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Christopher F Bell¹, Julie Priest^2,3, Justyna Amelio⁴, Xue Song⁵, Hong Kan⁶, Marni Stott-Miller⁷, Brendan Limone⁵, Virginia Noxon⁵ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁵Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁶Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁷GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. Methods: Retrospective…
Abstract Number: 2594 • 2017 ACR/ARHP Annual Meeting
Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Christopher F Bell¹, Julie Priest^2,3, Marni Stott-Miller⁴, Hong Kan⁵, Justyna Amelio⁶, Xue Song⁷, Brendan Limone⁷, Virginia Noxon⁷ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁵Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁶GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁷Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard…
Abstract Number: 2595 • 2017 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease
Hayley Epstein¹, Diana P. Pena², Bianca Di Cocco¹, Teja Kapoor³ and Anca Askanase⁴, ¹Rheumatology, CUMC, New York, NY, ²Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, ³Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: To evaluate the change in ANA titers as a proxy for progression in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxychloroquine (HCQ)…
Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Hua Chen¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…
Abstract Number: 2597 • 2017 ACR/ARHP Annual Meeting
Explorer Study: Rituximab Use in Systemic Lupus Erythematosus, a New Look on Old Data
Marc Scherlinger^1,2,3, Claire Carcaud^2,4, Thomas Barnetche^1,5, Lionel Couzy^2,6, Pierre Duffau^3,7,8, Estibaliz Lazaro^2,9 and Christophe Richez^2,10,11, ¹Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ²FHU ACRONIM, Bordeaux, France, ³UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ⁴Internal Medicine, Centre hospitalier universaire de Bordeaux, Bordeaux, France, ⁵FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France, ⁶Nephrology, Centre hospitalier universitaire de Bordeaux - Néphrologie, Bordeaux, France, ⁷Internal Medecine, Centre hospitalier universitaire de Bordeaux - Médecine interne, Bordeaux, France, ⁸FHU ACRONIM, bordeaux, France, ⁹Department of Internal Medecine and Clinical Immunology, Bordeaux University Hospital, Pessac, France, ¹⁰Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ¹¹UMR CNRS 5164 - Immunoconcept, bordeaux, France
Background/Purpose: Even if randomized trials EXPLORER and LUNAR failed to prove the superiority of rituximab versus placebo in patients with systemic lupus erythematosus, several encouraging…
Abstract Number: 2598 • 2017 ACR/ARHP Annual Meeting
The Effects of Tai Chi on Inflammatory Mediator Secretion in Systemic Lupus Erythematosus
Juliette Yedimenko¹, Evelyn Thomas², Brian Snoad³, Juhi Sharma², Misha Mobeen², Holly Steigelman¹, Alexa Meara⁴, Giancarlo R. Valiente⁵, Stacy P. Ardoin⁶, Nicole Powell⁷, John Sheridan⁷, Wael Jarjour⁸ and Nicholas A. Young³, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, OH, ³Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁷Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, ⁸Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Exercise and psychological stress have been shown to produce opposite effects on immunomodulation. Prior studies in patients with Systemic Lupus Erythematosus (SLE) have demonstrated…
Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Gaurav Sharma¹, Jasvinder A. Singh², Mohammed Sohaib Khaleel³ and Shristi Shrestha⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, UAB School of Medicine, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Molecular Cardiology, University of Louisville, Louisville, KY, ⁴Internal Medicine, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal
Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…
Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Cristina Arriens¹, Rufei Lu², Teresa Aberle², Stan Kamp², Wade DeJager², Melissa E. Munroe², Eliza Chakravarty¹, Katherine Thanou², Joan T. Merrill³, Joel M. Guthridge⁴ and Judith A. James³, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…
Abstract Number: 2601 • 2017 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
Jie An¹, Weinan Lai^2,3, Joshua Woodward⁴, Xizhang Sun¹, Lena Tanaka¹, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine/Division of Rheumatology, University of Washington, Seattle, WA, ³Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres…
Abstract Number: 2602 • 2017 ACR/ARHP Annual Meeting
Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients
Hiurma Sanchez-Perez¹ and David A. Isenberg², ¹Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Response to Rituximab (RTX) varies significantly between Systemic Lupus Erythematosus (SLE) patients. Ethnicity may play a role in these differences, and a possible relationship…
Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Gabriela Munhoz¹, Maira Lacerda¹, Michelle Lopes¹, Eduardo Ferreira Borba¹, Luciana Seguro² and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
Abstract Number: 2604 • 2017 ACR/ARHP Annual Meeting
The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
Ronald F van Vollenhoven¹, April Thompson², Bonnie Pobiner², Joe Eastman², Anne Hammer², James Groark³ and Damon Bass³, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK Collegeville, Collegeville, PA
Background/Purpose: Reduced corticosteroid use is considered a key goal in SLE treatment. This concept of ‘steroid-sparing’, seen with intravenous (IV) belimumab based on cumulative steroid…
Abstract Number: 2605 • 2017 ACR/ARHP Annual Meeting
Systematic Review, and Meta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized Placebo-Controlled Phase 3 Trials for Systemic Lupus Erythematosus
Shereen Oon^1,2, Molla Huq², Timothy Godfrey³ and Mandana Nikpour^1,2, ¹Rheumatology, St Vincent's Hospital, Melbourne, Australia, ²Medicine, The University of Melbourne, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia
Background/Purpose: There is a pressing need for novel biologic therapies in systemic lupus erythematosus (SLE). We sought to systematically review the outcomes of recent phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].